10/5/2010

Johnson & Johnson has received a complete-response letter from the FDA for an extended-release version of pain drug Nucynta. The agency asked for additional information about the treatment's conversion to a formulation designed to be break- and crush-resistant.

Full Story:
MSNBC

Related Summaries